CD70 and acute myeloid leukemia: Aberrantly expressed on AML LSCs and often upregulated at relapse. Blocking CD70 reduces leukemic engraftment in preclinical models. Absent on HSCs, but inducibly expressed on activated immune cells, which limits specificity. Under investigation in antibody- and CAR-T–based therapeutic trials